Literature DB >> 3106345

Fibrinogen lysine residue A alpha 157 plays a crucial role in the fibrin-induced acceleration of plasminogen activation, catalyzed by tissue-type plasminogen activator.

M Voskuilen, A Vermond, G H Veeneman, J H van Boom, E A Klasen, N D Zegers, W Nieuwenhuizen.   

Abstract

In previous studies, we have shown that the stretch 148-197 of the fibrinogen A alpha chain plays a crucial role in the acceleration of the tissue-type plasminogen activator (t-PA)-catalyzed plasminogen activation. In this study we have synthesized parts of A alpha 148-197 and analogues thereof. We found that the peptides with sequences identical with A alpha 148-161 and A alpha 149-161 of human fibrinogen accelerate the plasminogen activation by t-PA, whereas the corresponding peptides in which lysine residues A alpha 157 had been replaced by valine or arginine had no accelerating capacity. Furthermore, succinylation of the lysine residue(s) in the synthesized peptides A alpha 148-161 and A alpha 149-161 leads to loss of accelerating action. These findings show that lysine residue A alpha 157 is crucial for the accelerating action of fibrin on the t-PA-catalyzed plasminogen activation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3106345

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

Review 1.  Binding of plasminogen activators to fibrin: characterization and pharmacological consequences.

Authors:  R Fears
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

2.  The sequence A alpha-(148-160) in fibrin, but not in fibrinogen, is accessible to monoclonal antibodies.

Authors:  W J Schielen; M Voskuilen; G I Tesser; W Nieuwenhuizen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

3.  Fibrinogen Lima: a homozygous dysfibrinogen with an A alpha-arginine-141 to serine substitution associated with extra N-glycosylation at A alpha-asparagine-139. Impaired fibrin gel formation but normal fibrin-facilitated plasminogen activation catalyzed by tissue-type plasminogen activator.

Authors:  H Maekawa; K Yamazumi; S Muramatsu; M Kaneko; H Hirata; N Takahashi; C L Arocha-Piñango; S Rodriguez; H Nagy; J L Perez-Requejo
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

4.  Localization in the fibrinogen gamma-chain of a new site that is involved in the acceleration of the tissue-type plasminogen activator-catalysed activation of plasminogen.

Authors:  O Yonekawa; M Voskuilen; W Nieuwenhuizen
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

Review 5.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

6.  Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.

Authors:  R Pannell; S Li; V Gurewich
Journal:  J Thromb Thrombolysis       Date:  2017-08       Impact factor: 2.300

7.  Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.

Authors:  J I Weitz; B Leslie; J Ginsberg
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

8.  Structural requirements of position A alpha-157 in fibrinogen for the fibrin-induced rate enhancement of the activation of plasminogen by tissue-type plasminogen activator.

Authors:  J G Schielen; H P Adams; M Voskuilen; G J Tesser; W Nieuwenhuizen
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

9.  A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.

Authors:  J N Liu; V Gurewich
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

10.  Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK.

Authors:  Ralph Pannell; Shelley Li; Victor Gurewich
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.